graph Evidence gap map comparisons
afatinib based treatment
afatinib plus vinorelbine
la/mBC - HER2 positive - 2nd Line (L2) 13   
Comparator:  vs trastuzumab plus vinorelbine; 
Risk of bias:  low;   some concerns;   high;  NA;